cyrilzakka/clinical-trials huggingface dataset:
Radiofrequency for Chronic Post-mastectomy Pain: is it Better to Target Intercostal Nerves or Corresponding Dorsal Root Ganglia?

neuropathic pain can occur following any surgical procedure on the breast ..

chronic pain affects the daily lives of post-surgical breast cancer patients. many of these patients were undertreated for pain and generally obtained poor pain relief.treated patients with chronic thoracic segmental pain including patients with post-mastectomy pain syndrome by radiofrequency for dorsal root ganglion reported longterm pain relief.

Eligibility Criteria:
Inclusion Criteria:

* Patients with chronic post-mastectomy pain for at least 3 months post operatively.
* patients with visual analogue scale for pain score \> 4
* patients treated with more than one line of anti-neuropathic drugs.

Exclusion Criteria:

* patient refusal.
* coagulopathy.
* chest and back deformity.
* infection at the introduction site of the needle .
Linking Special Care Dentistry Curriculum to Seemingly Irrelevant Comedy

As Special care dentistry curriculum is very complicated and has a lot of details. Upon teaching it, the investigator will include memes and videos of movies and cartoons and will test the degree of retention of the information after years of passing the subject's exam.


Eligibility Criteria:
Inclusion Criteria:

* students in Ahram Canadian University.
* students who passed Special care dentistry course.
* students who were enrolled in the course from Fall 2021 to Summer 2023

Exclusion Criteria:

* Students who refused to answer the questionnaire
Evaluation of the Effects of Treatment of Psycho-stimulant and Cannabis-dependent Users in Israel

This study evaluates the effects of psychological and pharmacological treatment of regular users of cannabis and psychostimulants in a treatment center (Kfar Izun) in Israel. The participants will undergo psychological evaluation before and during treatment and follow up at 4 months. Ten participants will undergo brain imaging of the dopamine receptor D2 in order to evaluate the effects of treatment on dopamine turnover in the brain. A control group of psychiatric in-patients undergoing treatment for psychiatric illness with be recruited from Geha Hospital in Israel. It is predicted that successful treatment of regular users of cannabis will be resulted in improvement in anxiety, depression and psychotic symptoms as well as in upregulation of dopamine turnover in participants that will undergo brain imaging.

There is a significant number of cannabis and psychostimulant users that experience psychotic episodes and require psychiatric treatment. This study evaluates the effects of psychological and pharmacological treatment of regular users of cannabis and psychostimulants in a treatment center (Kfar Izun) in Israel. The participants will undergo psychological evaluation before and during treatment and follow up at 4 months. Ten participants will undergo brain imaging of the dopamine receptor D2 using \[I123\] IBZM in Single Photon Emitted Tomography (SPECT) before and after treatment in order to evaluate the effects of treatment on dopamine turnover in the brain. A control group of psychiatric in-patients undergoing treatment for psychiatric illness with be recruited from Geha Hospital in Israel.

Eligibility Criteria:
Inclusion Criteria:

* cannabis dependence with or without history of psychosis.

Exclusion Criteria:

* pregnant women
* under 18
* neurological damage
* HIV positive
* dependence on other drugs such as heroin
* cocaine or alcohol
Immuno-molecular Approaches for Non-invasive Diagnosis of Prostate Cancer

The purpose of this study is to isolate and characterize tumor cells non-invasively from biological samples in patients with prostate cancer and demonstrate the ability to identify the presence and number of tumor cells before prostate biopsy.

Prostate cancer is one of the most frequently diagnosed cancers and a leading cause of cancer death in men worldwide. Existing methods of diagnosis and monitoring of prostate cancer are inadequate due to their invasiveness, inaccuracy, cost, access uneven, etc., making difficult the diagnosis and patient's follow up. New techniques and methods are necessary to improve diagnosis.

Biological liquids might represent an attractive target to isolate prostate tumour cells for these purposes. In recent years, several studies have been carried out with the aim of reducing and / or avoiding the limits of sensitivity and specificity of current methods of screening for prostate cancer and thus obtain new biomarkers for the diagnosis and / or non-invasive monitoring.

However, due to technical and technological difficulties few studies have been performed to investigate the non-invasive isolation and direct analysis of tumour cells. Our project is therefore an innovative project which aims to study a new approach for the early diagnosis of prostate cancer, with better sensitivity and specificity.

Eligibility Criteria:
Inclusion Criteria:

* Patients with a diagnosis of localized or metastatic prostate cancer.
* No prior or other oncological treatment.
* Patients undergoing prostate biopsy in the context of prostate cancer diagnosis.
* Patients with an elevation of PSA (Prostate Specific Antigen), an abnormality on the rectal examination and / or an MRI signal motivating a prostate biopsy,
* Patients informed and not opposed to participating in the research

Exclusion Criteria:

* Patients not affiliated with French social security.
* Patients unable to understand the protocol.
* Patients diagnosed with another type of cancer within the past 5 years.
* Patients prostatectomized and/or treated for prostate cancer.
* Patients who wear a bladder catheter
* Patients under guardianship or curatorship
* Patients under AME
HRD and Resistance to PAPPi in EOC Patients

The association between homologous recombination (HR) gene mutations and homologous recombination deficiency (HRD) status in Chinese epithelial ovarian cancer (EOC) patients has been investigated in previous studies (NCT04190667 and NCT04651920). This study is to investigate the correlation between HRD and the resistance to poly(ADP-ribose) polymerase inhibitors (PARPi) in a Chinese cohort confirmed of epithelial ovarian cancer. The mutated genes, HRD score model and their relationship with the prognosis is the primary endpoint in this study. All enrolled patients will accept PARPi as maintenance therapy after the complete or partial remission of targeted lesions. A multiple panel testing of germline and somatic genes, including BRCA1/2, and HRD score are provided for all participants.


Eligibility Criteria:
Inclusion Criteria:

* Aged 18 years or older
* Pathological confirmation of epithelial ovarian cancer
* With available tumor tissues
* Given consents to participate the study
* With detailed follow-up outcomes

Exclusion Criteria:

* Not meeting all of the inclusion criteria
* Declining to accept PARPi as maintenance therapy after the major treatment for cancer
Clinical Validation of Medasense Pain Response Index (PRI)

In our previous study, NCT01631695, we proposed and clinically evaluated the Medasense pain response index, PRI, in anesthetized patients undergoing surgery. Note: the name PRI has been changed to NoL (Nociception Level) Index.

The PRI is based on a non-linear combination of several pain-related physiological parameters into a one unique index (0-100).

In this study we aim to validate the performance of the PRI by:

1. investigating the patient's PRI response to surgical painful stimuli under different levels of analgesia:

   * Investigating patient's PRI response to surgical painful stimuli under two different levels of Remifentanil Target Control Infusion (TCI) rates.
   * Investigating patient's PRI response to standardized painful stimulus (Tetanic stimulus) with and without opioids.
2. investigating the effect of beta-blockers on PRI performance in patients taking chronic beta-blocker treatment.

The study is based on recording and analyzing the subject's physiological signals, while recording painful events, medication dosing and different clinical signs.

Pain is an unpleasant sensation, ranging from slight discomfort to intense suffering. Since pain is a subjective phenomenon, it has frequently defied objective, quantitative measurements. Today, in order to measure pain, subjective uni-dimensional scales are used to quantify pain. One of the most common scale used to rate a patient's pain intensity is the Numeric Pain Scale (NPS), usually scored from 0 to 100. Hitherto, those scales are based on the subjective evaluation of pain by the patient.

During anesthesia the patient cannot communicate and therefore the verbal or other report is impossible. As a consequence, due to misrepresentation of the existence or extent of pain, care providers may fail to estimate the correct measure of pain and give too much or too little medication, leading to possible complications and adverse reactions. A validated scoring system of subject's pain level, or as in the case of an anaesthetised patient, subject's nociception level, is therefore needed.

In this study the investigators intend to test and analyze the performances of Medasense pain response index, PRI, by comparing it with other standard pain related indicators (Heart Rate (HR), Heart Rate Variability (HRV), Skin Conductance, etc) before and after painful stimuli at different levels of analgesia. In addition, in order to reduce the variability between stimuli, a standardized stimulus (Tetanic ,30 sec, 100Hz, 60mA) will be given to all patients after sleep induction and before intubation, with and without administration of Fentanyl and the values of the PRI during these stimuli will be investigated.

Eligibility Criteria:
Inclusion Criteria:

* ASA physical status 1-3
* Elective surgery

Exclusion Criteria:

* Pregnancy or lactation
* History of severe cardiac arrhythmias
* Abuse of alcohol or illicit drugs
* History of mental retardation, dementia, psychiatric disorders
* Allergy to any of the drugs to be used during anesthesia and recovery
Feasibility of Pharmaceutical Interventions in Elderly Heart Failure Patients.

Heart failure therapies (e.g. beta blockers) have been successful in decreasing mortality rates, as well as diminishing hospitalizations. Also, pharmacist collaboration has been shown to have a beneficial impact on heart failure related outcomes. Regardless, a high residual event rate is to be noted.

In our pilot study, we wished to document whether a clinical pharmacist could still play a role in the heart failure management of an elderly inpatient heart failure population.


Eligibility Criteria:
Inclusion Criteria:

* 75 years or older
* diagnosis of previous or new heart failure based on signs and symptoms as defined by the 'European Society of Cardiology guidelines on acute and chronic heart failure'
* diagnosis had to be confirmed by a recent echocardiogram

Exclusion Criteria:

* not Dutch speaking
* treatment restrictions had been applied on admission
Regenerative Surgical Treatment of Peri-implantitis Using Nanobone With or Without Simvastatin

The aim of this study was to evaluate the effect of using a synthetic bone substitute with or without simvastatin on regenerative surgical treatment of bone defects associated with peri-implantitis in a 6- months randomized controlled clinical trial.

A total of 30 patients diagnosed with peri-implantitis were randomly assigned to one of two surgical treatment groups (group I: synthetic bone substitute (NanoBone), group II: NanoBone with simvastatin). Clinical measurements included probing pocket depth (PPD), clinical attachment level (CAL), plaque index (PI), modified sulcus bleeding index (mSBI) and mucosal recession (MR). Radiographic bone fill was evaluated at baseline and after 6- months.

The study was designed as a prospective single-center, parallel group, 6 month randomized clinical trial evaluating the effect of a bone substitute; NanoBone® (Artoss GmbH, Rostock, Germany) (group 1, control group) compared to the same bone substitute with simvastatin (Corvast 80 mg, Egyphar, Egypt) (group 2, test group) for RST of peri-implantitis. A total of 30 patients suffering from peri-implantitis who needed regenerative treatment of at least one peri-implant bone defect were selected and only one implant per patient (the most severe) was evaluated in the treatment groups. The criteria for diagnosing peri-implantitis is based on the consensus report of the eighth European Workshop on Periodontology \[34\] ; the presence of a peri-implant marginal bone loss ≥2 mm based on baseline periapical radiographs after delivery of the final restoration and bleeding on probing (BOP) and/or suppuration with or without concomitant deepening of peri-implant pockets.

Clinical and radiographic evaluation were conducted at baseline and 6 months postoperatively. Grouping was done using a random number table generated by a third party. They were numbered according to the order of enrolment and assigned to group I or group II. The grouping results were sealed in an opaque envelope and kept by an independent third party. For each patient, cards opened immediately before the surgical procedures. Treatment assignment in each patient was registered by the clinician who assisted in the operations and kept concealed until the completion of the study.

Eligibility Criteria:
Inclusion Criteria:

1. age \> 18 years,
2. having at least one implant demonstrating bone defect ≥3 mm, which presented a probing depth of ≥5 mm with BOP and/or suppuration, implants had to be in function for \>12 months,
3. no implant mobility and no evidence of occlusal overload,
4. no evidence of occlusal overload
5. presence of at least 2 mm of keratinized attached mucosa .

Exclusion Criteria:

1. serious systemic diseases, medications or conditions that would contraindicate periodontal surgery and compromise wound healing,
2. history of taking systemic antibiotic during the past 3 months,
3. smoking,
4. pregnant or lactating females,
5. implants previously augmented with bone substitute or placed in grafted bone,
6. implants previously treated for peri-implantitis,
7. a mobile implant.
A Study to Evaluate Autologous CIK Cells in Patients With Hepatocellular Carcinoma After TACE, PEIT or RFA

A Phase I/II, Open Label Study to Evaluate the Safety and Efficacy of Autologous Cytokine-Induced Killer (CIK) Cell for Patients with Hepatocellular Carcinoma (HCC) after Transarterial Chemoembolization (TACE), Percutaneous Ethanol Injection Therapy (PEIT) or RadioFrequency Ablation (RFA) Therapy.


Eligibility Criteria:
Inclusion Criteria:

1. 20 to 80 years old men and women;
2. HCC diagnosed with typical imaging findings, or confirmed by needle liver biopsy;
3. Patients who are not a transplant candidate;
4. Patients who have no extrahepatic metastasis and are with measurable residual tumor after TACE, PEIT or RFA therapy;
5. Patients who have a life expectancy of at least 6 months;
6. Child-Pugh Class should be A or B;
7. Eastern Cooperative Oncology Group (ECOG) performance status score was 0-3;
8. Patients who have clinical laboratory test results as follows:

   * Absolute neutrophil count ≥ 1,500/µL or White blood cell ≥ 4,000/µL
   * Hemoglobin ≥ 8.5 g/dL
   * Platelet count ≥ 50,000/µL
   * Blood creatinine ≤ 1.5 x upper limit of normal
   * Total bilirubin \< 3 x upper limit of normal
   * Albumin ≥ 2.8 g/dL
   * International normalized ratio (INR) / Partial thromboplastin time (PTT) \< 1.5 x upper limit of normal
9. Written informed consent.

Exclusion Criteria:

1. Patients who have infiltrative or diffuse HCC;
2. Patients who have significant cardiovascular disease such as myocardial infarction occurred within recent 6 months, chronic heart failure or unstable coronary artery disease;
3. Patients who plan to receive systemic chemotherapy or target therapy;
4. Patients with other malignant tumor within the past 5 years before treatment;
5. Pregnant or lactating patients;
6. Patients with hemorrhage/bleeding event;
7. Patients with uncontrolled infections;
8. Known or suspected allergy to the investigational agent or any agent given in association with this trial;
9. Patients who have current Human Immunodeficiency Virus (HIV) or Treponema Pallidum (TP) infection;
10. Patients who are suffering from serious autoimmune disease;
11. Patients who have had long term use of or are using an immunosuppressant;
12. History of organ transplant;
13. Prior use of any anti-cancer treatments within 30 days or 5 half-lives (whichever is longer), except TACE, PEIT and RFA therapy;
14. Patients who have participated in another clinical study and received treatment within 30 days prior to the screening visit;
15. Mental conditions rendering the patient incapable of understanding the nature, scope, and consequences of the study;
16. Other situations that the researchers considered unsuitable for this study.
Impact of Cross-training on Induction Treatment Response in Acute Lymphoblastic Leukemia Adults

Despite advances in the treatment of acute lymphoblastic leukemia, the prognosis in adults is still poor, largely due to the resistance of treatment at diagnosis or early relapse. Among the strategies associated with the treatment of Acute Lymphoblastic Leukemia is rehabilitation and physical medicine in order to improve the quality of life, body composition, fitness, strength and improve the attachment and acceptance of their treatment

Previous evidence had shown that among the beneficial effects of an exercise intervention in cancer is the reduction of adverse events associated with treatment, such as nausea and fatigue. Also, the overexpression of Interleukin-15 in cancer is related to a poor prognosis, biologically the implementation of a cross-training exercise routine can function as a regulatory pathway for its expression due to its consumption at muscular level. Finally, the time to consider a relapse with a very poor prognosis is during first three months of treatment, so implementation of an exercise strategy during this period could reduce the proportion of early relapses mediated by Interleukin-15 expression

Eligibility Criteria:
Inclusion Criteria:

* Ability to walk without support.
* Life expectancy greater than 7 days
* Previous authorization of treating hematologist for participation
* Acceptance and signing of informed consent form

Exclusion Criteria:

* Patients with neutropenia, infections and / or bleeding on admission to hospitalization.
* Patients that are unable to perform physical activity.
* Central nervous system diseases that make movement impossible.
* Cardiac function alterations assessed by electrocardiogram and echocardiogram
* Patients in relapse
* Patients referred from another hospital and who are been attended in our hospital
Optimizing Iron Suppletion After Roux-en-Y Gastric Bypass

Multicentre randomized controlled trial to evaluate the optimal treatment for patients who developed an iron deficiency after Roux-en-Y Gastric bypass.

Morbid obesity is worldwide a still growing problem. The number of bariatric procedures are still increasing with 9000 bariatric operations in 2009. The golden standard is the Roux-en-Y Gastric bypass (RYGB). The RYGB ensures an excess weight loss of 60-70% in our hospital.

Unfortunately vitamin and mineral deficiencies are a consequence from RYGB. Iron deficiency occurs in 14-66% in the first two years after surgery. Worldwide there are three most used options of treatment for this: treatment with ferrous fumarate, ferrous gluconate and intravenous injection of Ferinject.

Our goal is to determine which treatment is the most effective to normalize ferritin values in the blood and which treatment is the most cost-effective one after a RYGB.

Eligibility Criteria:
Inclusion Criteria:

* all women who underwent a Roux-en-Y gastric bypass and developed an iron deficiency postoperatively (ferritin\<20microgram/L)

Exclusion Criteria:

* iron deficiency peroperative, blood transfusions during study period, iron containing nutritional supplements except the standard multivitamins after bariatric surgery, decreased renal failure, excessive blood loss due to menstruation, anemia not caused by iron deficiency, accumulation of iron, hypersensitivity for noe of the medicinal products, psychiatric illness, pregnancy
The Epidemiologic Study of Human Cytomegalovirus（CMV） in Female Students of Xiamen University

In this study, 100 female students aged 18 to 30 years old in Xiamen University will be enrolled. On the first visit, blood, saliva and urine samples of all participants will be collected. Then saliva and urine samples will be collected at two-week interval until 6 months. Serum samples will be tested the PP150-IgG titer. Saliva and urine samples will be used to test CMV DNA by PCR. The primary purpose of this study is to identify the relationship between baseline PP150-IgG titer and CMV infection.


Eligibility Criteria:
Inclusion Criteria:

* 18-30 years old
* female students of Xiamen University

Exclusion Criteria:

* students who have the serious diseases
Dexmedetomidine Addition to Morphine in Patients With Metastatic Cancer

Pain is a common symptom in patients nearing the end of life. Its prevalence varies between 30 and 75%. Nowadays, morphine is the most used molecule as first line treatment of moderate to severe pain. However, this molecule, considering its side effects, may contribute in part to the discomfort of these patients and may increase the pre-existing agitation or delirium. There is therefore a need to find new agents, other than morphine, for pain control at the end of life, without the limitations that the morphine molecule has. The author reviewed the literature on the role of dexmedetomidine in the treatment of refractory symptoms in palliative care, including pain. It is an agonist of the adrenergic alpha 2 receptor having a sedative, analgesic action and a morphine sparing effect demonstrated postoperatively.

This study aims primarily at demonstrating that dexmedetomidine has a beneficial role in the treatment of pain in patients with metastatic cancer.


Eligibility Criteria:
Inclusion Criteria:

* Any painful patient with metastatic cancer
* Whatever type of pain: nociceptive, neuropathic, or mixed
* Age \> 18 and \<75 years
* Patient under analgesic Tier III treatment: with moderate to severe pain and not relieved by non-opioid conventional treatment
* Patient cooperating capable of responding to the pain assessment by providing a number from 0 to 10 at the VAS
* Patient providing his explicit consent to participate in the study before inclusion (regardless of his inclusion in C or D Group)
* Patients with systolic blood pressure (SBP) ≥ 100 mmHg and a diastolic blood pressure (DBP) ≥ 50 mmHg
* Patients with a heart rate ≥ 50/min

Exclusion Criteria:

* Patient refusal to participate in the study or patient unable to give consent
* Age \<18 or \> 75 years
* Comatose uncooperative patient unable to respond to the assessment of pain by VAS
* Hypotensive patients with SBP \< 100 mmHg and DBP \< 60 mmHg or bradycardic with a heart rate \< 50/min
* Patient with a heart rhythm disorder, or a disorder of the atrial-ventricular conduction
* Patients under beta-blocker
* Patient with heart failure with an ejection fraction \< 40%
* Patient suffering from allergy or previous intolerance to morphine or dexmedetomidine
* Patient with renal impairment with a creatinine clearance \<3 0ml/min/1.73m2, or patient under hemodialysis or peritoneal dialysis.
* Patient with severe hepatic impairment with Child-Pugh score at C.